Pharming Group went into this earnings day with the stock under pressure, down roughly 39% over the past three months and closing at €0.8782. Yet the headline from the numbers is not collapse; it is a profitability reset that clashes with the gloomy share price trend. Q2 total revenue came in at US$90.2m with net income of US$1.6m, and earnings per share moved back into positive territory. The market is still trading Pharming Group like a problem story, while the income statement reads more like a controlled squeeze on margins during a difficult quarter.
Love that Pharming Group pushed earnings per share back into positive territory but worried the market still treats it like a problem stock after a 39% share price decline over three months? Take a look at our screener of 306 resilient stocks with low risk scores to see how this earnings setup compares with sturdier profiles.
Q2 2026 Earnings Summary
- Total Revenue (Q2 2026 vs Q2 2025): US$90.213m vs. US$93.221m (down 3.2%)
- Net Income (Excl. Extra Items, Q2 2026 vs Q2 2025): US$1.638m vs. US$4.694m (down 65.1%)
- Basic EPS (Q2 2026 vs Q2 2025): US$0.00239 vs. US$0.006838 (down 65.1%)
- Trailing 12 Month Total Revenue (Q2 2026 TTM vs Q2 2025 TTM): US$366.479m vs. US$320.708m (up 14.3%)
Prefer visual charts over scrolling through earnings tables and raw figures? Get a clear, full picture of Pharming Group, including its valuation at a glance, in our company report for Pharming Group.
Pharming bull case leans on Joenja execution
Bulls argue Pharming Group is successfully pivoting from a RUCONEST cash engine toward a Joenja led rare immunology franchise. The Q2 revenue mix provides some support. Joenja delivered US$17.9m and grew 40% y/y, with both U.S. and international markets contributing. Paid APDS patients reached 132 and identified U.S. APDS patients increased to 298, including 60 children aged 4 to 11, which directly links to the pediatric label expansion story. Management also kept adjusted operating profit positive while absorbing about US$9m of extra investment and lowered full year operating expense guidance, which aligns with the cost discipline narrative. The pipeline milestones are tracking, with both Phase II leniolisib studies fully enrolled and Q4 2026 readouts flagged. This is consistent with the plan to broaden beyond APDS.
Bear case tests RUCONEST pressure and guidance cut
The bear story is that Pharming Group remains over reliant on a pressured RUCONEST base and may be over promising on growth. Q2 stressed that risk. Total revenue fell 3% y/y and RUCONEST declined 10% y/y, as competition and international withdrawals weighed, even though sequential revenue improved 24%. Management cut 2026 revenue guidance by US$30m to US$375m to US$395m, so the earlier message of a firmer 2026 outlook has clearly been tempered. The revised midpoint implies only low single digit growth versus 2025, which aligns more closely with the cautious view. Q2 operating cash outflow of US$9.7m and heavier R&D also fit the concern that funding the pipeline keeps pressure on cash generation, even with high gross margins and a US$159.5m cash balance.
After a guidance cut, heavier R&D and volatile trading in Pharming Group, review our independent risk scoring and explore potential structural blind spots in the risk analysis for Pharming Group which shows 2 important warning signs.Stay Ahead With Simply Wall St
If the mix of a 39% three month share price decline and Pharming Group returning to positive earnings per share has your attention, register for free with Simply Wall St and add it to a Watchlist to track price against fair value and watch how the thesis evolves. Once you own any position, use the Portfolio Command Center to cut through market noise and focus on the key updates that matter for your holdings. For a broader perspective on Pharming Group and other stocks, turn to the Community and see how different investors are interpreting the same data. This helps you surface potential catalysts and risks earlier so you can stay ahead of the market.
Seeking Alternatives Beyond Pharming Group?
Fresh ideas often move first when momentum builds and quality stocks are identified before the wider market pays attention. Scan these curated lists while they are still relatively under the radar.
- Target steadier portfolio anchors by scanning a curated 306 resilient stocks with low risk scores that focuses on resilience while others chase what is already moving.
- Explore potential income opportunities with a focused set of 432 dividend fortresses that aim to keep cash returns front and center.
- Consider early growth stories through carefully filtered 524 high quality undiscovered gems that many investors have not yet evaluated in depth.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com